| Bioactivity | IRAK4-IN-7 is a selective, potent and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, extracted from patent WO2015104688 (example 1). IRAK4-IN-7 has the potential for cancer and inflammatory diseases treatment[1]. | ||||||||||||
| In Vivo | IRAK4-IN-7 has anti-cancer and anti-inflammatory activities, it can be used for cancer and inflammatory diseases treatment[1]. | ||||||||||||
| Name | IRAK4-IN-7 | ||||||||||||
| CAS | 1801343-74-7 | ||||||||||||
| Formula | C21H19N7O3 | ||||||||||||
| Molar Mass | 417.42 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Venkateshwar Rao GUMMADI, et al. Bicyclic heterocyclyl derivatives as irak4 inhibitors. WO2015104688A1. |